The latest people and business news from the past month, all in one place.
Suvoda has tapped Irena Lerentracht Webster to join its board of directors. With over 20 years of experience at a drug development leader at the sponsor, CRO, and site levels, Webster currently serves as VP head of program strategy & development operations for Arkuda Therapeutics.
Parexel announced the appointment of Anne G. Kasmar, MD, MSc, as SVP, Global Therapeutic Area Head — Infectious Disease and Vaccines. Previously, Kasmar was a lead medical director at Genentech, South San Francisco, California, where she oversaw cross-functional teams researching new therapies for graft-versus-host disease as well as novel antibiotics.
ArisGlobal revealed the hiring of expansion of its executive team. Ann-Marie Orange joins as chief technology officer, after previously serving as CIO for TransUnion. Glenn Renzulli has been recruited as the new chief financial officer. Prior to joining ArisGlobal, Renzulli worked as chief financial officer of Paya.
Dr. Vince Clinical Research announced the receipt of a Two Green Globes certification to its clinical pharmacology unit
M3 Wake Research is expanding operations into Charleston, SC with the opening of a clinical research practice.
Phastar has been certified as a Certified B Corporation®, coming after a 12-month review to ensure protocols and procedures reflect the company’s commitment to high environment, social, and governance (EGS) standards.
OneStudyTeam announced that StudyTeam is now being used by more than 4,000 clinical research sites outside the United States, bringing the total to 7,000 in more than 100 countries.
Almac Group opened a a new custom-built GMP warehouse and dispatch hub at its Global Headquarters in Craigavon, UK.
AARDEX Group announced its place as a founding member of the CancerX initiative, aiming to drive innovation and improve follow up for cancer patients.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.